Provided by Tiger Trade Technology Pte. Ltd.

Johnson & Johnson

236.54
-1.0600-0.45%
Volume:5.37M
Turnover:1.27B
Market Cap:569.89B
PE:21.45
High:238.29
Open:236.83
Low:235.13
Close:237.60
52wk High:251.71
52wk Low:141.50
Shares:2.41B
Float Shares:2.40B
Volume Ratio:1.23
T/O Rate:0.22%
Dividend:5.14
Dividend Rate:2.17%
EPS(TTM):11.03
EPS(LYR):11.03
ROE:35.03%
ROA:8.68%
PB:6.99
PE(LYR):21.44

Loading ...

J&J - Adverse Reactions for Icotyde Within 1.1% of Placebo Through Week 16; No New Safety Signals Through Week 52

THOMSON REUTERS
·
Mar 18

FDA Approval of Icotyde™ (Icotrokinra) Ushers in New Era for First-Line Systemic Treatment of Plaque Psoriasis With a Targeted Oral Peptide

THOMSON REUTERS
·
Mar 18

J&J - Icotyde Met All Primary Efficacy Endpoints in Four Phase 3 Studies With 2,500 Patients

THOMSON REUTERS
·
Mar 18

Nippon Shinyaku and Johnson & Johnson start co-promotion of Opsumit pediatric tablets in Japan

Reuters
·
Mar 18

Judge overturns $950M talc trial award against Johnson & Johnson, Reuters says

TIPRANKS
·
Mar 18

RGP appoints Jessica Harris as supply chain practice leader

Reuters
·
Mar 17

J & J Snack Foods (JJSF) Gets a Hold from Jefferies

TIPRANKS
·
Mar 17

HSBC Adjusts Price Target on Johnson & Johnson to $280 From $265, Maintains Buy Rating

MT Newswires Live
·
Mar 17

U.S. RESEARCH ROUNDUP- Biogen, Eli Lilly, Johnson & Johnson

Reuters
·
Mar 17

Johnson & Johnson : HSBC Raises Target Price to $280 From $265

THOMSON REUTERS
·
Mar 17

Perrigo Co. PLC Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Mar 17

Monte Rosa Therapeutics Announces Clinical Supply Agreement To Support Phase 2 Trial Evaluating Mrt-2359 In Combination With Apalutamide For The Treatment Of Metastatic Castration-Resistant Pros

Reuters
·
Mar 16

J&J announces Phase 1 study of erdafitinib met primary safety endpoint

TIPRANKS
·
Mar 16

BUZZ-Monte Rosa rises on lining up new combo trial in advanced prostate cancer

Reuters
·
Mar 16

Monte Rosa to launch Phase 2 trial of MRT-2359 plus apalutamide in AR-mutant mCRPC in Q3 2026

Reuters
·
Mar 16

Monte Rosa Therapeutics Inc - to Conduct and Sponsor Trial; Johnson & Johnson to Supply Erleada

THOMSON REUTERS
·
Mar 16

What Are Defensive Stocks? Best Defensive Stocks to Buy in 2026

TradingKey
·
Mar 16

Perrigo Co. PLC Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
Mar 14

J&J says erdafitinib met primary safety endpoint in Phase 1 study

TIPRANKS
·
Mar 14

Johnson & Johnson Phase 1 Erda-iDRS trial reports 89% complete response rate in intermediate-risk bladder cancer

Reuters
·
Mar 14